260 related articles for article (PubMed ID: 23535281)
1. Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI.
Horovitz DD; Magalhães TS; Acosta A; Ribeiro EM; Giuliani LR; Palhares DB; Kim CA; de Paula AC; Kerstenestzy M; Pianovski MA; Costa MI; Santos FC; Martins AM; Aranda CS; Correa Neto J; Holanda GB; Cardoso L; da Silva CA; Bonatti RC; Ribeiro BF; Rodrigues Mdo C; Llerena JC
Mol Genet Metab; 2013 May; 109(1):62-9. PubMed ID: 23535281
[TBL] [Abstract][Full Text] [Related]
2. Galsulfase: arylsulfatase B, BM 102, recombinant human arylsulfatase B, recombinant human N-acetylgalactosamine-4-sulfatase, rhASB.
Drugs R D; 2005; 6(5):312-5. PubMed ID: 16128602
[TBL] [Abstract][Full Text] [Related]
3. Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey study.
Horovitz DDG; Leão EKEA; Ribeiro EM; Martins AM; Barth AL; Neri JICF; Kerstenetzky M; Siqueira ACM; Ribeiro BFR; Kim CA; Santos FC; Franco JFS; Lichtvan LCL; Giuliani LR; Rodrigues MDCS; Bonatti RCF; Teixeira TB; Gonçalves A; Lourenço CM; Pereira ASS; Acosta AX
Mol Genet Metab; 2021 May; 133(1):94-99. PubMed ID: 33678523
[TBL] [Abstract][Full Text] [Related]
4. Up to five years experience with 11 mucopolysaccharidosis type VI patients.
Brands MM; Oussoren E; Ruijter GJ; Vollebregt AA; van den Hout HM; Joosten KF; Hop WC; Plug I; van der Ploeg AT
Mol Genet Metab; 2013 May; 109(1):70-6. PubMed ID: 23523338
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy.
Garcia P; Phillips D; Johnson J; Martin K; Randolph LM; Rosenfeld H; Harmatz P
Mol Genet Metab; 2021 May; 133(1):100-108. PubMed ID: 33775523
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI.
Furujo M; Kubo T; Kosuga M; Okuyama T
Mol Genet Metab; 2011 Dec; 104(4):597-602. PubMed ID: 21930407
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures.
Harmatz P
Turk J Pediatr; 2010; 52(5):443-9. PubMed ID: 21434527
[TBL] [Abstract][Full Text] [Related]
8. The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
Harmatz P; Hendriksz CJ; Lampe C; McGill JJ; Parini R; Leão-Teles E; Valayannopoulos V; Cole TJ; Matousek R; Graham S; Guffon N; Quartel A;
Mol Genet Metab; 2017 Sep; 122(1-2):107-112. PubMed ID: 28457718
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.
Ruane T; Haskins M; Cheng A; Wang P; Aguirre G; Knox VW; Qi Y; Tompkins T; O'Neill CA
Mol Genet Metab; 2016 Feb; 117(2):157-63. PubMed ID: 26776148
[TBL] [Abstract][Full Text] [Related]
10. Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen.
Auclair D; Finnie J; White J; Nielsen T; Fuller M; Kakkis E; Cheng A; O'Neill CA; Hopwood JJ
Mol Genet Metab; 2010 Feb; 99(2):132-41. PubMed ID: 19896877
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age--a sibling control study.
McGill JJ; Inwood AC; Coman DJ; Lipke ML; de Lore D; Swiedler SJ; Hopwood JJ
Clin Genet; 2010 May; 77(5):492-8. PubMed ID: 19968667
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy.
Braunlin E; Rosenfeld H; Kampmann C; Johnson J; Beck M; Giugliani R; Guffon N; Ketteridge D; Sá Miranda CM; Scarpa M; Schwartz IV; Leão Teles E; Wraith JE; Barrios P; Dias da Silva E; Kurio G; Richardson M; Gildengorin G; Hopwood JJ; Imperiale M; Schatz A; Decker C; Harmatz P;
J Inherit Metab Dis; 2013 Mar; 36(2):385-94. PubMed ID: 22669363
[TBL] [Abstract][Full Text] [Related]
13. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
[TBL] [Abstract][Full Text] [Related]
14. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study.
Giugliani R; Lampe C; Guffon N; Ketteridge D; Leão-Teles E; Wraith JE; Jones SA; Piscia-Nichols C; Lin P; Quartel A; Harmatz P
Am J Med Genet A; 2014 Aug; 164A(8):1953-64. PubMed ID: 24764221
[TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy outcomes across the disease spectrum: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program.
Harmatz PR; Lampe C; Parini R; Sharma R; Teles EL; Johnson J; Sivam D; Sisic Z
J Inherit Metab Dis; 2019 May; 42(3):519-526. PubMed ID: 30834539
[TBL] [Abstract][Full Text] [Related]
16. Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme]).
Kim KH; Decker C; Burton BK
Pediatrics; 2008 Mar; 121(3):e714-7. PubMed ID: 18250117
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
Brunelli MJ; Atallah ÁN; da Silva EM
Cochrane Database Syst Rev; 2016 Mar; 3():CD009806. PubMed ID: 26943923
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
Brunelli MJ; Atallah ÁN; da Silva EM
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD009806. PubMed ID: 34533215
[TBL] [Abstract][Full Text] [Related]
19. Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats.
Auclair D; Finnie J; Walkley SU; White J; Nielsen T; Fuller M; Cheng A; O'Neill CA; Hopwood JJ
Pediatr Res; 2012 Jan; 71(1):39-45. PubMed ID: 22289849
[TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement therapy initiated in adulthood: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program.
Lampe C; Harmatz PR; Parini R; Sharma R; Teles EL; Johnson J; Sivam D; Sisic Z
Mol Genet Metab; 2019 Aug; 127(4):355-360. PubMed ID: 31324526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
